focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Johnson Set For Brexit Talks With French President

Thu, 22nd Aug 2019 07:50

(Alliance News) - UK Prime Minister Boris Johnson on Thursday is set for showdown Brexit talks in Paris, hours after French President Emmanuel Macron ruled out making concessions.

The UK government was buoyed on Wednesday after comments by German Chancellor Angela Merkel which seemed to indicate that European leaders could be willing to renegotiate the Withdrawal Agreement in a bid to avoid a no-deal Brexit.

Hosting Johnson at the Chancellery in Berlin, Merkel set Britain a 30-day deadline for coming up with an alternative solution to replace the Irish backstop – a bid to avoid a hard border in Northern Ireland after the UK's exit from the EU by keeping Britain aligned with certain regulations set by Brussels.

But Macron told reporters on Wednesday that the demands to renegotiate the Brexit deal were "not an option".

He said: "We have to help the British deal with this internal democratic crisis but we mustn't be hostage to it nor export it."

The frank comments could make Johnson's trip to the Elysee Palace a dicey affair, with the Conservative Party leader set to meet his French counterpart for lunch on Thursday at his official residence to discuss changing the terms of Britain's exit.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.4% at 7,177.90

----------

Hang Seng: down 0.9% at 26,032.40

Nikkei 225: closed up 0.1% at 20,628.01

DJIA: closed up 0.9% at 26,202.73

S&P 500: closed up 0.8% at 2,924.43

----------

GBP: down at USD1.2113 (USD1.2131)

EUR: down at USD1.1076 (USD1.1097)

Gold: down at USD1,501.56 per ounce (USD1,503.01)

Oil (Brent): firm at USD60.14 a barrel (USD60.75)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Thursday's Key Economic Events still to come

US Fed's Jackson Hole economic policy symposium opens

1100 BST UK CBI Distributive Trades Survey

1100 BST Ireland WPI

0830 CEST Switzerland Industrial Production

0845 CEST France New home sales

0915 CEST France Flash PMI

0930 CEST Germany Flash PMI

1000 CEST Eurozone Flash PMI

1330 CEST ECB accounts from last monetary policy meeting

1600 CEST EU FCCI Flash Consumer Confidence Indicator

0830 EDT Canada Wholesale trade

0830 EDT Canada Employment Insurance

0830 EDT US Unemployment Insurance Weekly Claims Report - Initial Claims

0945 EDT US US Flash Manufacturing PMI

0945 EDT US US Flash Services PMI

1030 EDT US EIA Weekly Natural Gas Storage Report

----------

US Federal Reserve will remain flexible and interest rates will not be on a "preset course" despite persistent risks from trade uncertainty and weak global growth, the central bank said Wednesday. Although the minutes of the Fed's policy meeting late last month showed officials were primarily focused on the risks to the US economy, amid fears about the blowback from President Donald Trump's trade war with Beijing, they stressed that they would keep their options open on their next steps. While they made no mention of Trump's constant attacks on Fed Chairman Jerome Powell, officials said they would be "guided by incoming information and its implications for the economic outlook" and avoid "any appearance of following a preset course," according to the minutes of the Fed's July 30-31 policy meeting. The July rate cut was viewed as "part of a recalibration... or mid-cycle adjustment" and, given the uncertainty surrounding the outlook, the officials "highlighted the need for policymakers to remain flexible and focused on the implications of incoming data for the outlook." However, the minutes showed the central bankers are not unified, with several opposed to cutting rates while a couple favored a bigger cut.

----------

A hard border on the island of Ireland would make a US-UK trade deal "highly unlikely", the UK prime minister has been warned. The Congressional Friends of Ireland, a group in the US Congress which supports and promotes peace and reconciliation in Northern Ireland, has written to Boris Johnson warning that it will oppose any US-UK trade deal if it risks undermining the Good Friday Agreement. According to the letter: "The US, and the more than 33 million Americans with Irish ancestry, share a genuine interest in the continued success of the Good Friday Agreement and the hard-won peace and prosperity it has brought to so many. That is why we strongly oppose any unravelling of the historic treaty or a return of a physical border on the island of Ireland under any circumstances. "We will oppose any US-UK trade deal if the Good Friday Agreement is undermined."

----------

US trade policies, including the trade war with China, will shrink US economic output by 0.3 percentage points by 2020, the US Congressional Budget Office said Wednesday. The report by the non-partisan government agency contradicts President Donald Trump's claims that the tariffs imposed on Chinese goods and Chinese retaliatory tariffs are not harming the US economy. "Tariffs reduce domestic GDP mostly by raising domestic prices, thereby reducing the purchasing power of consumers and increasing the cost of business investment," CBO Director Phillip Swagel said in a statement. US GDP growth is projected to slow from 2.5% in 2018 to 2.3% in 2019. Earlier this month, Trump unexpectedly postponed additional punitive tariffs on Chinese imports to December, anticipating adverse effects on consumer shopping ahead of the Christmas holiday.

----------

BROKER RATING CHANGES

----------

LIBERUM CUTS ANGLO AMERICAN TO 'SELL' ('HOLD') - TARGET 1500 (2200) PENCE

LIBERUM CUTS RIO TINTO TO 'SELL' ('HOLD') - TARGET 3300 (4500) PENCE

LIBERUM CUTS BHP GROUP TO 'SELL' ('HOLD') - TARGET 1400 (2000) PENCE

----------

COMPANIES - FTSE 100

----------

Building materials firm CRH reported interim profit growth and expanded its share buyback programme. Revenue for the first half of 2019 came in at EUR13.22 billion, up from EUR11.94 billion a year ago. Pretax profit rose to EUR707 million from EUR497 million. "On the back of our strategic initiatives, CRH has delivered significant profit growth in the first half of 2019, with a good performance in our heritage business and strong contributions from recent acquisitions," said Chief Executive Albert Manifold. He added: "We are pleased to report that the board plans to continue our share buyback programme with a further tranche of EUR350 million to be completed by year end. This will bring our total share repurchases in 2019 to EUR900 million."

----------

AstraZeneca said roxadustat has been approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease. AstraZeneca and FibroGen China are collaborating on the development and commercialisation of roxadustat in China. FibroGen China, based in Beijing, is a wholly-owned subsidiary of FibroGen Inc.

----------

UAE-focused private healthcare firm NMC Health backed its annual guidance after a solid first half. Revenue for the first half of 2019 rose to USD1.24 billion from USD932.0 million, with pretax profit rising to USD140.6 million from USD118.7 million. NMC said it continues to view the future "with confidence" and reiterated its annual guidance. Separately, the company also said it intends to launch a USD200 million share buyback programme.

----------

COMPANIES - FTSE 250

----------

Animal genetics firm Genus said Finance Director Stephen Wilson has been promoted to the role of chief executive, with effect from "the close of business" on September 13. Current CEO Karim Bitar in March said he would be stepping down to head up ConvaTec. Wilson's finance responsibilities will be undertaken by Janet Duane, currently financial controller on an interim basis. A search for a permanent replacement finance director has already commenced.

----------

Gaming firm Playtech set out share buyback plans despite posting a fall in profit. Revenue for the six months to June 30 was EUR736.1 million, versus just EUR436.5 million a year ago. Pretax profit, however, fell to EUR28.0 million from EUR124.2 million after the firm booked EUR108.6 million in depreciation and amortisation charges, versus just EUR60.6 million a year ago. In addition, Playtech recognised a EUR87.4 million fair value gain on equity investments in the year ago period, which fell to just EUR141,000 in the first half of 2019. Playtech halved its interim dividend to 6.1 euro cents from 12.1 cents a year ago but, including a planned EUR25 million buyback, total shareholder returns were up 15% year-on-year for the half.

----------

COMPANIES - OTHER MAIN MARKET AND AIM

----------

Ryanair has lost a High Court bid to block strike action by its UK pilots – hours after winning a similar legal move in Dublin. A judge sitting in London on Wednesday rejected an urgent application by the airline for an injunction against the British Airline Pilots' Association. The decision by Justice Lambert came after Ryanair succeeded at the High Court in Dublin earlier on Wednesday in its bid to prevent pilots based in Ireland from going on a 48-hour strike from midnight on Thursday. The airline sought an urgent injunction from the judge in London just hours before the start of threatened industrial action by members of Balpa in a dispute over pay and conditions. After hearing submissions from Ryanair and Balpa, the judge dismissed the various grounds raised by the airline. Strike action by UK Ryanair pilots is due to take place on Thursday and Friday, with a second round of dates in September.

----------

Thursday's Shareholder Meetings

D4T4 Solutions

Castings

----------

London Briefing is available to subscribers as an email newsletter. Contact info@alliancenews.com

More News
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.